JAZZ News and Press, Jazz Pharmaceuticals plc From 03/16/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Interest rates are back in the spotlight with a Federal Reserve interest rate decis...

Noteworthy events during the week of March 17 - 23 for healthcare investors. More news on: SCYNEXIS, Inc., Sage Therapeutics, Inc., Intrexon Corporation, Healthcare stocks news, , Read more ...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/14/2019. Please visit our Tracking Ole Andreas Halvorsen&#...

DUBLIN , March 5, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Cowen and Company 39th Annual Healthcare Conference in Boston, MA. Matt Young , executive vice president and chief...

Jazz Pharmaceuticals, Inc. (JAZZ) Q4 2018 Earnings Conference Call February 26, 2019, 04:30 PM ET Company Participants Katherine Littrell - Head of IR Bruce Cozadd - Chairman and Chief Executive Officer Matthew Young - Executive Vice President and Chief Financial Officer Daniel...

The following slide deck was published by Jazz Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more ...

Gainers: TNDM   +14.6% . JAZZ   +9.1% . FTR   +11.3% . DF   +9.0% . PANW   +8.0% . More news on: Tandem Diabetes Care, Inc., Jazz Pharmaceuticals, Inc., Frontier Communications Corporation, Stocks on the move, Read more ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) Q4 results ($M): Revenues: 476.5 (+9.2%). More news on: Jazz Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q4 Non-GAAP EPS of $3.64 beats by $0.62 ; GAAP EPS of $2.64 beats by $0.65 . Revenue of $476.5M (+9.2% Y/Y) beats by $16.83M . Shares +9.8% . Press Release More news on: Jazz Pharmaceuticals, Inc., Earnings news and commentary, Stocks on th...

Total Revenues Increased 17% to $1.9 Billion in 2018 GAAP Diluted EPS of $7.30 ; Adjusted Diluted EPS of $13.70 Launched Vyxeos for AML in the EU and Initiated Broad Development Program Received U.S. Approval of Xyrem for Pediatric Narcolepsy Submitted the MAA to EMA fo...